AstraZeneca looks to new CKD combinations to extend Farxiga’s reign

It’s been nearly 10 years since Farxiga was first approved to treat Type II diabetes, and AstraZeneca is taking its life cycle management strategy beyond new indications for the SGLT2 inhibitor, and into new combinations. The goal is to reach subsets of patients who don’t respond to monotherapy.

Farxiga dapagliflozin works via a general mechanism that can be applied across cardiorenal diseases, and AstraZeneca plc (LSE:AZN; NYSE:AZN) has gained label expansions for heart failure and chronic kidney disease since its initial diabetes approval. The drug, an SGLT2 inhibitor, helps preserve kidney function by removing excess glucose and sodium from the blood and reducing blood pressure in the kidneys...